Advertisement

Intrathecal infusion of Baclofen for spasticity: the Toulouse and the French Multicenter Studies

  • Y. Lazorthes
  • J. C. Verdié
  • B. Sallerin-Caute
  • R. Bastide

Abstract

Since 1984, 20 patients were treated with chronic intrathecal administration of Baclofen.

Keywords

Intrathecal Administration Intrathecal Baclofen Sodium Dantrolene Severe Spasticity Intrathecal Infusion 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Babinski J (1912) Réflexes tendineux et reflexes osseux. Bull MedGoogle Scholar
  2. Birkmayer W, Danielczyk W, Weiler G (1967) Zur Objektivierbarkeit des myotonolytischen Effctes eines Aminobutter Säurederivates (CIBA). Wien Med Wschr 117:7–9PubMedGoogle Scholar
  3. Blackshear PJ, Dormon FD, Blackshear PJ Jr (1972) The design and initial testing of an implantable infusion pump. Surg Gynecol Obstet 134:51–56PubMedGoogle Scholar
  4. Bormann J (1988) Electrophysiology of GABA-A and GABA-B receptor sybtypes. TINS 11(3):112–116PubMedGoogle Scholar
  5. Bowery NG, Hill OR, Hudson AL, Doble A, Middlemiss DN, Shaw J, Turnbull M (1980) Baclofen decreases neurtransmitter release in the mammalian CNS by an action at a novel GABA receptor. Nature (Lond) 283:92–94CrossRefGoogle Scholar
  6. Bowery NG, Price GW, Hudson AL, Hill DR, Wilkin GP, Turnbull MJ (1984) GABA receptor multiplicity. Visualization of different receptor types in the mammalian CNS. Neuropharmacology 23(2B):219–231PubMedCrossRefGoogle Scholar
  7. Bowery NG, Hudson AL, Price GW (1987) GABA-A and GABA-B receptor site distribution in the rat central nervous system. Neuroscience 20(2):365–383PubMedCrossRefGoogle Scholar
  8. Colbert N, Izrael V, Renaud J, Laugier A (1948) Chimiotherapie anti-cancéreuse et pompes implantables. Concours Med 106(25):2376–2380Google Scholar
  9. Curtis DR, Gynther BD, Beattie DT, Kerr DIB, Prager RH (1988) Baclofen antagonism by 2-hydroxy-Badofen in the cat spinal cord. Neurosci Lett 92:97–101PubMedCrossRefGoogle Scholar
  10. Dolphin AC, Scott RH (1987) Calcium channel currents and their inhibition by Baclofen in rat sensory neurons modulation by guanine nucleotides. J Physiol (Lond) 386:1–17Google Scholar
  11. Dunlap K (1986) Two types of gamma-aminobutyric acid receptor on embryonic sensory neurons. Br J Pharmacol 74:579–585CrossRefGoogle Scholar
  12. Ensminger W, Niederhuber J, Dakhil S, Thrall J, Wheeler R (1981) Totally implanted drug delivery system for hepatic arterial chemotherapy. Cancer Treat Rep 65:393–400PubMedGoogle Scholar
  13. Erickson DL., Michaelson M (1989) Control of intractable spasticity with intrathecal morphine sulfate. Neurosurgery 24(2):236–238CrossRefGoogle Scholar
  14. Faigle JW, Keberle H (1972) The metabolism and pharmacokinetics of Lioresal. In: Birmayer W (ed) Spasticity — a topical survey. Huber, Bern, pp 94–100Google Scholar
  15. Gahwiler BH, Brown DA (1985) GABA-B receptor activated K + current in voltage-clamped CA3 pyramidal cells in hyppocampal cultures. Proc Natl Acad Sci USA 82:1558–1562PubMedCrossRefGoogle Scholar
  16. Hankey GJ, Stewart-Wynne EG, Perlman D (1986) Intrathecal Baclofen for severe spasticity. Med J Aust 145(9):465–466PubMedGoogle Scholar
  17. Innis RB, Nestler EJ, Aghajanian GK (1988) Evidence for G protein mediation of serotonin-and GABA-B-induced hyperpolarization of rat dorsal raphe neurons. Brain Res 459:27–36PubMedCrossRefGoogle Scholar
  18. Jerusalem F (1968) Doppelblindstudie iiber den antispastischen EfTekt von ß-(4-Chlorophenyl)-aminobuttersäure (CIBA) bei multipler Sklerose. Nervenarzt 39:515–517PubMedGoogle Scholar
  19. Kerr BBI, Ong J, Prager RH, Gynther BD, Curtis DR (1987) Phaclofen: a peripheral and central Baclofen antagonist. Brain Res 405:150–154PubMedCrossRefGoogle Scholar
  20. Kerr DIB, Ong J, Johnson GAR, Abbenante J, Prager RH (1988) 2-hydroxy-Saclofen: an improved antagonist at central and peripheral GABA-B receptors. Neurosci Lett 92:92–96PubMedCrossRefGoogle Scholar
  21. Kerr DIB, Ong J, Johnston GAR, Berthelot P, Debaert M, Vaccher C (1989) Benzofuram analogues of Baclofen: a new class of central and peripheral GABA-B receptor antagonists. Eur J Pharmacol 164:361–364PubMedCrossRefGoogle Scholar
  22. Knutsson E, Lindblom U, Martensson A (1974) Plasma and cerebrospintal fluid levels of Baclofen (Lioresal®) at optimal therapeutic responses in spastic paresis. J Neurol Sci 23:473–484PubMedCrossRefGoogle Scholar
  23. Kroin JS, Penn RD. Cerebrospinal fluid pharmacokinetics of lumbar intrathecal Baclofen. Personal communicationGoogle Scholar
  24. Kroin JS, Penn RD, Beissinger RL, et al (1984) Reduced spinal reflexes following intrathecal baclofen in the rabbit. Exp Brain Res 54:191–194PubMedCrossRefGoogle Scholar
  25. Kroin JS, Singh R, Penn RD, Bianchi GD (1989) Chronic intrathecal Baclofen reduces GABA-B binding in rat substantia gelatinosa. Receptor modulation: up and down regulation 1. Soc Neurosci Abstr 15:975 (389.10)Google Scholar
  26. Latach ML, Penn RD, Corcos DM, Gottlieb GL (1989) Short-term effects of intrathecal baclofen in spasticity. Exp Neurol 103:165–172CrossRefGoogle Scholar
  27. Latash ML, Penn R, Corcos D, Gottlieb G (1990) Intrathecal Baclofen unmasks residual voluntary motor control in spasticity. J Neurosurg 72:388–392PubMedCrossRefGoogle Scholar
  28. Lazorthes Y (1985) Neuropharmacologie en application intrathécale. In: Siegfried J, Lazorthes Y (eds) La neurochirurgie Fonctionnelle de l’Infirmité Motrice Cérébazle. Neurochirurgie 31 [Suppl 1]:95–101Google Scholar
  29. Lazorthes Y (1987) Chronic intrathecal administration of baclofen in severe spasticity. In: Ensminger WD, Selan JL (eds) Infusion systems in medecine. Futura Publishing, Mount Kisco NY, pp 327–336Google Scholar
  30. Lazorthes Y (1988) Chronic intrathecal administration of Baclofen in treatment of severe chronic spasticity. In: Muller H, Ziersky J, Penn R (eds) Local spinal therapy of spasticity. Springer, Berlin Heidelberg New York Tokio, pp 215–222CrossRefGoogle Scholar
  31. Lazorthes Y, Sallerin-Caute B, Verdie J-C, Bastide R, Carillo JP (1990) Chronic intra-thecal Baclofen administration for control of severe spasticity. J Neurosurg 72:393–402PubMedCrossRefGoogle Scholar
  32. Müller H, Zierski J, Dralle D, Borner U, Hoffmann O (1987) The effect of intra-thecal Baclofen on electrical muscle activity in spasticity. J Neurol 234(5):348–352PubMedCrossRefGoogle Scholar
  33. Müller H, Zierski J, Penn RD (1988) Local spinal therapy of spasticity. Springer, Berlin Heidelberg New York Tokio, pp 155–214CrossRefGoogle Scholar
  34. Müller H, Zierski J, Dralle D, Hoffmann O, Michaelis G (1988) Intrathecal baclofen in spasticity. In: Muller H, Zierski J, Penn RD (eds) Local spinal therapy of spasticity. Springer, Berlin Heidelberg, pp 155–214CrossRefGoogle Scholar
  35. Müller-Schwefe G, Penn RD (1989) Physostigmine in the treatment of intrathecal Baclofen overdose. J Neurosurg 71:273–275PubMedCrossRefGoogle Scholar
  36. Müller-Schwefe G, Penn RD, Kroin JS. Physostigmine in the treatment of intrathecal Baclofen overdose. Personal communicationGoogle Scholar
  37. Parke B, Penn RD, Savoy SM, Corcos D (1989) Functional outcome following delivery of intrathecal baclofen in patients with multiple sclerosis and spinal cord injury. Arch Phys Med Rehab 70:30–32Google Scholar
  38. Penn RD (1988) Chronic intrathecal baclofen for severe rigidity and spasms. In: Muller H, Zierski J, Penn RD (eds) Local spinal therapy of spasticity. Springer, Berlin Heidelberg New York Tokio, pp 151–154CrossRefGoogle Scholar
  39. Penn RD, Kroin JS (1984) Intrathecal baclofen alleviates spinal cord spasticity. Lancet i:1078CrossRefGoogle Scholar
  40. Penn RD, Kroin JS (1985) Continuous intrathecal baclofen for severe spasticity. Lancet ii:125–127CrossRefGoogle Scholar
  41. Penn RD, Kroin JS (1987) Long-term intrathecal baclofen infusion for treatment of spasticity. J Neurosurg 66:181–185PubMedCrossRefGoogle Scholar
  42. Penn RD, Savoy S, Corcos D, Latash M, Gottlieb T, Parke B, Kroin J (1989) Intrathecal Baclofen for severe spinal spasticity. N Engl J Med 320(23):1517–1521PubMedCrossRefGoogle Scholar
  43. Price GWX, Wilkin GP, Turnbull MJ, Bowery NG (1984) Are Baclofen-sensitive GAB A-B receptors present on primary apparent terminals of the spinal cord? Nature 307(5946):71–74PubMedCrossRefGoogle Scholar
  44. Price GW, Kelly JS, Bowery NG (1987) The location of GABA-B receptor binding sites in mammalian spinal cord. Synapse 1(6):530–538PubMedCrossRefGoogle Scholar
  45. Sallerin-Caute B, Monsarrat B, Lazorthes Y, Cros J, Bastide R (1980) A sensitive method for the determination of Baclofen in human CSF by high performance liquid chromatography. J Liquid Chromatogr 11(8):1753–1761Google Scholar
  46. Schmid K, Bohmer G, Gebauer K (1989) GABA-B receptor mediated effects on central respiratory system and their antagonism by Phaclofen. Neurosci Lett 99:305–310PubMedCrossRefGoogle Scholar
  47. Siegfried J, Rea GL (1987) Intrathecal application of baclofen in the treatment of spasticity. Acta Neurochir 39:121–123CrossRefGoogle Scholar
  48. Zierski J, Müller H (1988) Implantation of parts and pumps. Technique for intra-thecal administration of drugs. In: Müller H, Zierski J, Penn R (eds) Local spinal therapy of spasticity. Springer, Berlin Heidelberg New York Tokio, pp 215–222Google Scholar

Copyright information

© Springer-Verlag Wien 1991

Authors and Affiliations

  • Y. Lazorthes
    • 1
  • J. C. Verdié
    • 1
  • B. Sallerin-Caute
    • 1
  • R. Bastide
    • 1
  1. 1.Department of NeurosurgeryHopital de RangueilToulouseFrance

Personalised recommendations